Effects of Steady-State Lopinavir/Ritonavir on the Pharmacokinetics of Pitavastatin in Healthy Adult VolunteersMORGAN, Roger E; CAMPBELL, Stuart E; SUEHIRA, Kazuhito et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 2, pp 158-164, issn 1525-4135, 7 p.Article

Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in ChildrenBEST, Brookie M; CAPPARELLI, Edmund V; DIEP, Huy et al.Journal of acquired immune deficiency syndromes (1999). 2011, Vol 58, Num 4, pp 385-391, issn 1525-4135, 7 p.Article

A Lopinavir/Ritonavir-Based Once-Daily Regimen Results in Better Compliance and Is Non-inferior to a Twice-Daily Regimen Through 96 WeeksMOLINA, Jean-Michel; PODSADECKI, Thomas J; JOHNSON, Margaret A et al.AIDS research and human retroviruses. 2007, Vol 23, Num 12, pp 1505-1514, issn 0889-2229, 10 p.Article

Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavirPHAM, Paul A; FLEXNER, Charles; PARSONS, Teresa et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 45, Num 2, pp 201-205, issn 1525-4135, 5 p.Article

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavirLUBOMIROV, Rubin; DI IULIO, Julia; LEDERGERBER, Bruno et al.Pharmacogenetics and genomics (Print). 2010, Vol 20, Num 4, pp 217-230, issn 1744-6872, 14 p.Article

Lopinavir Tablet Pharmacokinetics With an Increased Dose During PregnancyBEST, Brookie M; STEK, Alice M; MIROCHNICK, Mark et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 54, Num 4, pp 381-388, issn 1525-4135, 8 p.Article

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy VolunteersKISER, Jennifer J; GERBER, John G; PREDHOMME, Julie A et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 47, Num 5, pp 570-578, issn 1525-4135, 9 p.Article

Detection of intrapulmonary concentration of lopinavir in an HIV-infected patientATZORI, Chiara; VILLANI, Paola; REGAZZI, Mario et al.AIDS (London). 2003, Vol 17, Num 11, pp 1710-1711, issn 0269-9370, 2 p.Article

Lopinavir-ritonavir : Effects on endothelial cell function in healthy subjectsGRUBB, Jessica R; DEJAM, André; VOELL, Jocelyn et al.The Journal of infectious diseases. 2006, Vol 193, Num 11, pp 1516-1519, issn 0022-1899, 4 p.Article

Gemfibrozil ConcentrationsAre Significantly Decreased in the Presence of Lopinavir-RitonavirBUSSE, Kristin H; HADIGAN, Colleen; CHAIREZ, Cheryl et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 52, Num 2, pp 235-239, issn 1525-4135, 5 p.Conference Paper

Predictors of Loss of Virologic Response in Subjects Who Simplified to Lopinavir/Ritonavir Monotherapy from Lopinavir/Ritonavir Plus Zidovudine/LamivudineCAMPO, Rafael E; DA SILVA, Barbara A; COTTE, Laurent et al.AIDS research and human retroviruses. 2009, Vol 25, Num 3, pp 269-275, issn 0889-2229, 7 p.Article

Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1-infected PatientsEDEN, Arvid; ANDERSSON, Lars-Magnus; TUNBÄCK, Petra et al.AIDS research and human retroviruses. 2010, Vol 26, Num 5, pp 533-540, issn 0889-2229, 8 p.Article

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoringBOFFITO, Marta; BACK, David J; HOGGARD, Patrick G et al.AIDS (London). 2003, Vol 17, Num 7, pp 1107-1108, issn 0269-9370, 2 p.Article

Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoproteinVISHNUVARDHAN, Daesety; VON MOLTKE, Lisa L; RICHERT, Clemens et al.AIDS (London). 2003, Vol 17, Num 7, pp 1092-1094, issn 0269-9370, 3 p.Article

Efficacy and Safety of Switching From Boosted Lopinavirto Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZI P StudyMALLOLAS, Josep; PODZAMCZER, Daniel; ALBERTO ARRANZ, José et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 1, pp 29-36, issn 1525-4135, 8 p.Article

A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenJOHNSON, Margaret A; GATHE, Joseph C; PODZAMCZER, Daniel et al.Journal of acquired immune deficiency syndromes (1999). 2006, Vol 43, Num 2, pp 153-160, issn 1525-4135, 8 p.Article

Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patientsMARCELIN, Anne-Geneviève; COHEN-CODAR, Isabelle; PEIGUE-LAFEUILLE, Hélène et al.Antimicrobial agents and chemotherapy. 2005, Vol 49, Num 5, pp 1720-1726, issn 0066-4804, 7 p.Article

Prediction of early and confirmed virological response by genotypic inhibitory quotients for lopinavir in patients naïve for lopinavir with limited exposure to previous protease inhibitorsTORTI, Carlo; UCCELLI, Maria Cristina; PATRONI, Andrea et al.Journal of clinical virology. 2006, Vol 35, Num 4, pp 414-419, issn 1386-6532, 6 p.Article

The Pharmacokinetics of Lersivirine (UK-453,061) and HIV-1 Protease Inhibitor Coadministration in Healthy SubjectsVOURVAHIS, Manoli; LANGDON, Grant; LAYTON, Gary et al.Journal of acquired immune deficiency syndromes (1999). 2012, Vol 60, Num 1, pp 24-32, issn 1525-4135, 9 p.Article

Functional defect caused by the 4544G>A SNP in ABCC2: potential impact for drug cellular dispositionELENS, Laure; TYTECA, Donatienne; PANIN, Nadtha et al.Pharmacogenetics and genomics (Print). 2011, Vol 21, Num 12, pp 884-893, issn 1744-6872, 10 p.Article

Lopinavir―Ritonavir Monotherapy Versus Lopinavir―Ritonavir and 2 Nucleosides for Maintenance Therapy of HIV: 96-Week AnalysisARRIBAS, Jose R; DELGADO, Rafael; SANCHEZ-CONDE, Matilde et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 2, pp 147-152, issn 1525-4135, 6 p.Article

Loss of Bone Mineral Density After Antiretroviral Therapy Initiation, Independent of Antiretroviral RegimenBROWN, Todd T; MCCOMSEY, Grace A; KING, Martin S et al.Journal of acquired immune deficiency syndromes (1999). 2009, Vol 51, Num 5, pp 554-561, issn 1525-4135, 8 p.Article

Reduced lopinavir exposure during pregnancySTEK, Alice M; MIROCHNICK, Mark; COTTER, Amanda et al.AIDS (London). 2006, Vol 20, Num 15, pp 1931-1939, issn 0269-9370, 9 p.Article

Coadministration of lopinavir/ritonavir and phenytoin results in two-way drug interaction through cytochrome P-450 inductionLIM, Michael L; MIN, Sherene S; ERON, Joseph J et al.Journal of acquired immune deficiency syndromes (1999). 2004, Vol 36, Num 5, pp 1034-1040, issn 1525-4135, 7 p.Article

The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentrationBIERMAN, Wouter Fw; VAN VONDEREN, Marit Ga; VELDKAMP, Agnes I et al.Antiviral therapy (London). 2011, Vol 16, Num 5, pp 647-655, issn 1359-6535, 9 p.Article